QCM
BEAM icon

Quantinno Capital Management’s Beam Therapeutics BEAM Stock Holding History

Quantinno Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$383K Buy
16,076
+8,607
+115% +$239K ﹤0.01% 2895
2025
Q4 		$207K Buy
+7,469
New +$191K ﹤0.01% 3041

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Quantinno Capital Management's BEAM Position: Q1 2026 in Review

Quantinno Capital Management increased its Beam Therapeutics (BEAM) stake by 115% in Q1 2026, buying an estimated $239K and bringing the position to 16,076 shares worth $383K. The position accounts for ﹤0.01% of the portfolio, ranked #2895.

Quantinno Capital Management first reported a position in BEAM in Q4 2025 and has held it in 2 quarters since. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Quantinno Capital Management held 16,076 shares of Beam Therapeutics worth $383K as of Q1 2026.
  • Quantinno Capital Management bought 8,607 Beam Therapeutics shares in Q1 2026, an estimated $239K.
  • Beam Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q1 2026, its #2895 holding.
  • Quantinno Capital Management first reported a position in Beam Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Quantinno Capital Management's 13F filing for Q1 2026, filed 15 May 2026.